These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

732 related articles for article (PubMed ID: 26552009)

  • 1. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.
    Kim KH; Kim W; Howard TP; Vazquez F; Tsherniak A; Wu JN; Wang W; Haswell JR; Walensky LD; Hahn WC; Orkin SH; Roberts CW
    Nat Med; 2015 Dec; 21(12):1491-6. PubMed ID: 26552009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
    Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
    Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
    Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
    Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation.
    Pyziak K; Sroka-Porada A; Rzymski T; Dulak J; Łoboda A
    Drug Dev Res; 2021 Sep; 82(6):730-753. PubMed ID: 33565092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2:
    Chan-Penebre E; Armstrong K; Drew A; Grassian AR; Feldman I; Knutson SK; Kuplast-Barr K; Roche M; Campbell J; Ho P; Copeland RA; Chesworth R; Smith JJ; Keilhack H; Ribich SA
    Mol Cancer Ther; 2017 May; 16(5):850-860. PubMed ID: 28292935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The spectrum of SWI/SNF mutations, ubiquitous in human cancers.
    Shain AH; Pollack JR
    PLoS One; 2013; 8(1):e55119. PubMed ID: 23355908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
    Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
    PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease.
    Kadoch C; Copeland RA; Keilhack H
    Biochemistry; 2016 Mar; 55(11):1600-14. PubMed ID: 26836503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers.
    Bitler BG; Aird KM; Garipov A; Li H; Amatangelo M; Kossenkov AV; Schultz DC; Liu Q; Shih IeM; Conejo-Garcia JR; Speicher DW; Zhang R
    Nat Med; 2015 Mar; 21(3):231-8. PubMed ID: 25686104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
    McCabe MT; Ott HM; Ganji G; Korenchuk S; Thompson C; Van Aller GS; Liu Y; Graves AP; Della Pietra A; Diaz E; LaFrance LV; Mellinger M; Duquenne C; Tian X; Kruger RG; McHugh CF; Brandt M; Miller WH; Dhanak D; Verma SK; Tummino PJ; Creasy CL
    Nature; 2012 Dec; 492(7427):108-12. PubMed ID: 23051747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors.
    Baker T; Nerle S; Pritchard J; Zhao B; Rivera VM; Garner A; Gonzalvez F
    Oncotarget; 2015 Oct; 6(32):32646-55. PubMed ID: 26360609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer.
    Shain AH; Giacomini CP; Matsukuma K; Karikari CA; Bashyam MD; Hidalgo M; Maitra A; Pollack JR
    Proc Natl Acad Sci U S A; 2012 Jan; 109(5):E252-9. PubMed ID: 22233809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ARID1A-deficiency in urothelial bladder cancer: No predictive biomarker for EZH2-inhibitor treatment response?
    Garczyk S; Schneider U; Lurje I; Becker K; Vögeli TA; Gaisa NT; Knüchel R
    PLoS One; 2018; 13(8):e0202965. PubMed ID: 30138427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
    Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
    PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BAFfling pathologies: Alterations of BAF complexes in cancer.
    Arnaud O; Le Loarer F; Tirode F
    Cancer Lett; 2018 Apr; 419():266-279. PubMed ID: 29374542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition.
    Drosos Y; Myers JA; Xu B; Mathias KM; Beane EC; Radko-Juettner S; Mobley RJ; Larsen ME; Piccioni F; Ma X; Low J; Hansen BS; Peters ST; Bhanu NV; Dhanda SK; Chen T; Upadhyaya SA; Pruett-Miller SM; Root DE; Garcia BA; Partridge JF; Roberts CWM
    Mol Cell; 2022 Jul; 82(13):2472-2489.e8. PubMed ID: 35537449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting EZH2 and PRC2 dependence as novel anticancer therapy.
    Xu B; Konze KD; Jin J; Wang GG
    Exp Hematol; 2015 Aug; 43(8):698-712. PubMed ID: 26027790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The SWI/SNF Complex: A Frequently Mutated Chromatin Remodeling Complex in Cancer.
    Nguyen VT; Tessema M; Weissman BE
    Cancer Treat Res; 2023; 190():211-244. PubMed ID: 38113003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early-Stage Induction of SWI/SNF Mutations during Esophageal Squamous Cell Carcinogenesis.
    Nakazato H; Takeshima H; Kishino T; Kubo E; Hattori N; Nakajima T; Yamashita S; Igaki H; Tachimori Y; Kuniyoshi Y; Ushijima T
    PLoS One; 2016; 11(1):e0147372. PubMed ID: 26812616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.